Gilead Sciences (GILD) Other Accumulated Expenses (2011 - 2026)

Gilead Sciences (GILD) has reported Other Accumulated Expenses for 12 consecutive years, with $3.4 billion the latest figure, recorded in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $3.4 billion, down 26.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.4 billion (down 26.35% YoY), and the FY2025 annual result was $4.0 billion, down 27.65% from the prior year.
• Other Accumulated Expenses was $3.4 billion for Q1 2026 at Gilead Sciences, down from $4.0 billion in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $5.9 billion in Q3 2023 and troughed at $3.4 billion in Q1 2026.
• Average Other Accumulated Expenses over 5 years is $4.6 billion, with a median of $4.5 billion recorded in 2022.
• Year-over-year, Other Accumulated Expenses gained 12.01% in 2023 and declined 27.65% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $4.6 billion in 2022, then climbed by 12.01% to $5.1 billion in 2023, then advanced by 6.51% to $5.5 billion in 2024, then decreased by 27.65% to $4.0 billion in 2025, then slipped by 14.01% to $3.4 billion in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $3.4 billion in Q1 2026, $4.0 billion in Q4 2025, and $3.8 billion in Q3 2025.